Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

Dengue is the most prevalent mosquito-borne viral disease; endemic to 100 countries worldwide, with more than half the world’s populations at-risk AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development for...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials